Email this article Format for printing

Amgen (AMGN) By Zeke Ashton (TMF Centaur) Second-Quarter Update Released: 8/9 Date Summary 8/9/00 Amgen Positions Itself for Long-Term Success 5/15/00 FREE! Amgen Sluggish in First Quarter as Attention Turns to New Product Candidates 2/14/00 Leading the Way to the Future of Biotech Amgen (Nasdaq: AMGN) is the clear top dog and first mover in the biotechnology universe. Powered by sales of two of the most successful biotechnology-derived drugs of all time, Amgen has rung up awesome gains for the company's shareholders over the last decade. With patent expiration for Amgen's top two revenue producing drugs looming ever closer, how will Amgen continue to maintain and extend its impressive lead over the rest of the industry? Amgen will spend an estimated $850 million for research and development in 2000 in its search for new therapeutic products. Zeke Ashton explores Amgen's product pipeline in search of the potential blockbuster drug that will keep Amgen on top of the biotech world of the 21st century, and he will provide an ongoing, regularly updated framework for investing in this immensely rewarding but highly volatile sector.

More Research Reports Get unlimited access to company reports for one year. Complete List of Companies We're Covering Other Subscription Options Amgen Resources Amgen Quotes & Data Amgen Discussion Board Amgen Website Search the Fool for Articles on Amgen Back to Research Center

 More Stock Research